The Cyclin Dependent Kinase 13 pipeline drugs market research report outlays comprehensive information on the Cyclin Dependent Kinase 13 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Cyclin Dependent Kinase 13 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Breast Cancer, and Ovarian Cancer. It also reviews key players involved in Cyclin Dependent Kinase 13 targeted therapeutics development with respective active and dormant or discontinued products.
The Cyclin Dependent Kinase 13 pipeline targets constitutes close to seven molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in IND/ CTA Filed, Preclinical, and Discovery stages are 1, 4, and 1 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Cyclin Dependent Kinase 13 overview
Cyclin-Dependent Kinase 13 (CDK13) is a member of the cyclin-dependent kinase family, which plays a crucial role in regulating the cell cycle. CDK13 is involved in the transcriptional regulation of gene expression rather than traditional cell cycle control. CDK13 forms a complex with cyclin K and is associated with the positive transcription elongation factor b (P-TEFb) complex. This complex is implicated in the regulation of RNA polymerase II-mediated transcriptional elongation. CDK13 phosphorylates the C-terminal domain of RNA polymerase II, contributing to the release of paused RNA polymerase II and allowing efficient transcription elongation. The activity of CDK13 is thought to impact various cellular processes, including the expression of genes involved in cell proliferation, differentiation, and response to environmental cues. Dysregulation of CDK13 has been associated with certain cancers, highlighting its potential as a therapeutic target.
For a complete picture of Cyclin Dependent Kinase 13’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
